Medpace Holdings, Inc. is a clinical contract research organization (CRO) that provides outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company offers full-service Phase I-IV clinical trial support, including clinical trial management, patient recruitment, clinical monitoring, regulatory affairs, medical writing, biometrics, pharmacovigilance, and quality assurance. Medpace operates central, bioanalytical, and core laboratories for specialized testing, imaging, and cardiovascular services, as well as clinics for studies in healthy volunteers and patient populations. Its proprietary information management system, ClinTrak, supports real-time study metrics and data integration. The company serves small, mid-sized, and large biopharmaceutical companies globally, with particular therapeutic expertise in oncology, metabolic disorders, cardiology, antiviral and anti-infective diseases, and the central nervous system. Medpace’s laboratories and clinics are located in the United States, Belgium, China, and Singapore.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage medpace.com
Sector Healthcare IR page investor.medpace.com
Tags
clinical trials, contract research, biopharmaceuticals, oncology, cardiology, central nervous system, metabolic disorders, antiviral, biostatistics, pharmacovigilance, bioanalytical testing, medical devices, ClinTrak
Press page —

Metrics

Valuation  
Market cap $ 19.297B
Market cap (USD) $ 19.297B
P/E 38.29
PEG 1.70
P/BV 32.99
P/S 6.80
P/OCF 26.69
P/FCF 28.90
Dividend yield —
Turnover / mcap —
Returns  
ROE 70.2%
ROI 596.2%
ROIC 588.0%
Profit margin 17.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 22.5%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 18
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 2.53B 2.109B 1.886B 1.46B 1.142B 925.925M 860.969M 704.589M 436.152M 421.582M 359.059M
Net profit 451.123M 404.386M 282.81M 245.368M 181.848M 145.384M 100.443M 73.185M 39.122M 13.425M -8.673M
Free cash flow 681.867M 572.267M 396.726M 351.171M 235.056M 227.336M 183.955M 140.56M 85.661M 78.195M 79.405M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 561.65 332.23 306.53 212.41 217.64 139.2 84.06 52.93 36.26 36.07 —
Price performance 12m 0.69 0.08 0.44 -0.02 0.56 0.66 0.59 0.46 0.01 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 79.8M 83.1M 133M 156M 161M 186M 253M 298M 296M 402M
↳ YoY growth +22.6% +4.2% +60.6% +16.6% +3.4% +15.8% +35.9% +17.8% -0.7% +35.6%
↳ 5y CAGR +19.9% +18.5% +25.0% +17.5% +13.8% +20.1%
Borrowings, current (USD) 12.4M 16.5M 0.00 — — 0.00 50M 0.00 — —
Borrowings, non-current (USD) 151M 205M 79.7M 0.00 — — — — — —
Lease liabilities (USD) — — 0.00 56.2M 131M 147M 158M 164M 150M 137M
Cash and deposits (USD) 37.1M 26.5M 23.3M 132M 278M 461M 28.3M 245M 669M 497M
Intangible assets (USD) 136M 98.7M 69.2M 54.4M 46.5M 41.4M 38M 35.8M 34.4M 33.4M
Right-of-use assets (USD) — — 0.00 52.2M 114M 130M 139M 145M 129M 118M
Net debt (borrowings + leases - cash) (USD) 127M 195M 56.4M -75.7M — -314M 180M -81M — —
Cash flow detail
Operating cash flow (USD) 91.7M 97.4M 157M 202M 259M 263M 388M 433M 609M 713M
Purchases of property, plant and equipment (USD) -13.5M -11.7M -16M -17.9M -31.3M -28.3M -36.9M -36.6M -36.5M -31.4M
Purchases of intangible assets (USD) 0.00 -569,000 0.00 0.00 — — — — — —
Change in receivables (cash effect) (USD) -13.7M -2.9M -27M -21.3M -5.53M -25M -66.9M -48.3M 2.24M -106M
Change in payables (cash effect) (USD) 691,000 4.82M 1.34M 4.73M -2.6M 1.87M 6.43M 1.05M -2.97M 2.63M
Share buybacks (cash effect) (USD) 0.00 -156M 0.00 0.00 -98.3M -62.1M -848M -144M -170M -917M
Interest paid (cash effect) (USD) -16.9M -6.89M -7.59M -1.49M -104,000 -123,000 -2.94M -3.06M -171,000 0.00
Income taxes paid (cash effect) (USD) -17.7M -17.2M -23.3M -13.2M -23.1M -56.2M -50.2M -76.4M -83.6M -39.7M
Share-based compensation (USD) 9.82M 4.46M 6.5M 20.7M 13.8M 14.5M 21.4M 20.5M 25.5M 34.8M
Operating cash flow before change in receivables (USD) 105M 100M 184M 223M 264M 288M 455M 482M 607M 819M
Free cash flow (OCF - PPE - intangibles) (USD) 78.2M 85.1M 141M 184M 227M 235M 351M 397M 572M 682M
Income detail
Total comprehensive income (USD) 12.2M 42.1M 71.4M 100M 148M 177M 238M 285M 400M 461M
Comprehensive income to owners (USD) 12.2M 42.1M 71.4M 100M 148M 177M 238M 285M 400M 461M
Provision for credit losses (USD) 2.17M 250,000 791,000 263,000 167,000 -11,000 0.00 3.42M 113,000 29,000
Credit cost ratio (credit losses / average receivables) (%) 3.0% 0.3% 0.7% 0.2% 0.1% 0.0% 0.0% 1.2% 0.0% 0.0%
Reported Feb 27, 2018 Feb 27, 2018 Apr 30, 2019 Feb 25, 2020 Feb 16, 2021 Oct 25, 2022 Feb 14, 2023 Feb 13, 2024 Feb 11, 2025 Feb 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

October 21, 2026

PDF Version

  • Revenue of $716.0 million in the third quarter of 2026 increased 8.5% from revenue of $659.9 million for the comparable prior-year period, representing a backlog conversion rate of 23.8%.

  • Net new business awards were $873.4 million in the third quarter of 2026, representing an increase of 10.6% from net new business awards of $789.6 million for the comparable prior-year period.

  • Third quarter of 2026 GAAP net income was $137.5 million, or $4.84 per diluted share, versus GAAP net income of $111.1 million, or $3.86 per diluted share, for the comparable prior-year period. Net income margin was 19.2% and 16.8% for the third quarter of 2026 and 2025, respectively.

  • EBITDA was $172.1 million for the third quarter of 2026, an increase of 16.0% from EBITDA of $148.4 million for the comparable prior-year period, resulting in an EBITDA margin of 24.0%.

CINCINNATI--(BUSINESS WIRE)--Oct. 21, 2026-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Results

Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0 million, compared to $659.9 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025.

Backlog as of September 30, 2026 increased 5.6% to $3,167.2 million from $3,000.6 million as of September 30, 2025. Net new business awards were $873.4 million, as compared to $789.6 million for the comparable prior-year period.

For the third quarter of 2026, total direct costs were $492.1 million, compared to total direct costs of $463.0 million in the third quarter of 2025. Selling, general and administrative (SG&A) expenses were $51.8 million in the third quarter of 2026, compared to SG&A expenses of $48.1 million in the third quarter of 2025.

GAAP net income for the third quarter of 2026 was $137.5 million, or $4.84 per diluted share, versus GAAP net income of $111.1 million, or $3.86 per diluted share, for the third quarter of 2025. This resulted in a net income margin of 19.2% and 16.8% for the third quarter of 2026 and 2025, respectively.

EBITDA for the third quarter of 2026 increased 16.0% to $172.1 million, or 24.0% of revenue, compared to $148.4 million, or 22.5% of revenue, for the comparable prior-year period. On a constant currency basis, EBITDA for the third quarter of 2026 increased 16.0% from the third quarter of 2025.

A reconciliation of the Company’s non-GAAP financial measures, including EBITDA and EBITDA margin to the corresponding GAAP measures is provided below.

Year-to-Date 2026 Financial Results

Revenue for the nine months ended September 30, 2026 was $2,129.9 million, and increased 16.9% on a reported basis and 16.7% on a constant currency basis from the comparable prior-year period. Year-to-date 2026 GAAP net income was $382.7 million, or $13.37 per diluted share, compared to $316.0 million, or $10.64 per diluted share, for the comparable prior-year period. Year-to-date 2026 EBITDA was $474.9 million, or 22.3% of revenue, and increased 19.5% on a reported basis and 20.4% on a constant currency basis from the comparable prior-year period.

Balance Sheet and Liquidity

The Company’s Cash and cash equivalents were $705.3 million at September 30, 2026, and the Company generated $216.6 million in cash flow from operating activities during the third quarter of 2026. There were no share repurchases in the third quarter of 2026. As of September 30, 2026, the Company had $527.0 million remaining under its authorized share repurchase program.

Effective October 20, 2026 (“Effective Date”), the Company’s Board of Directors (“Board”) terminated the Company’s current stock repurchase authorization of the Company’s common stock, $0.01 par value (“common stock”) which was set to expire on December 31, 2026. As of the Effective Date, this repurchase authorization had $527.0 million remaining.

Effective as of the Effective Date, the Board approved a new stock repurchase authorization, pursuant to which the Company is authorized to repurchase up to $1.0 billion shares of common stock until December 31, 2028, at the discretion of the Company’s management. Repurchases under this new authorization may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to alternative uses of capital, prevailing market conditions, applicable regulatory requirements, and other considerations. Under the new authorization, any such repurchases may be executed using open market purchases, privately negotiated transactions, transactions in accordance with Rule 10b5-1 of the Exchange Act, or other transactions, and will be funded from cash on hand. The new authorization does not obligate the Company to acquire any minimum amount of common stock and the new authorization may be modified, limited, extended, suspended or terminated by the Board at any time without prior notice.

2026 Financial Guidance

The Company forecasts 2026 revenue in the range of $2.835 billion to $2.855 billion, representing growth of 12.0% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $514.0 million to $524.0 million. Additionally, full year 2026 EBITDA is expected in the range of $638.0 million to $652.0 million. Based on forecasted 2026 revenue of $2.835 billion to $2.855 billion and GAAP net income of $514.0 million to $524.0 million, diluted earnings per share (GAAP) is forecasted in the range of $17.97 to $18.32. This guidance assumes a full year 2026 tax rate of 19.0% to 19.5%, interest income of $22.9 million, foreign exchange rates as of September 30, 2026, and 28.6 million diluted weighted average shares outstanding. This guidance does not include the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after September 30, 2026.

Conference Call Details

Medpace will host a conference call at 9:00 a.m. ET, Thursday, October 22, 2026, to discuss its third quarter 2026 results.

To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,600 people across 46 countries as of September 30, 2026.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” “forecast,” “may,” “could,” “likely,” “project,” “goal,” “objective,” “potential,” “range,” “estimate,” “preliminary,” “opportunity,” “outlook,” “trend,” “can,” “might,” “drives,” “hope,” “future,” “predict” and similar expressions, and variations or negatives of these words. However, the absence of these words does not mean that a statement is not forward-looking.

These forward-looking statements are largely based on management’s current expectations and projections about future events and financial trends that we believe may affect, among other things, our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other factors that may cause our financial condition, actual results, performance (including share price performance), or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the potential loss, delay or non-renewal of our contracts, or the non-payment by customers for services we have performed; the failure to convert backlog to revenue at our present or historical conversion rate(s); the failure to maintain or generate new business awards; fluctuation in our results between fiscal quarters and years; the risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases; decreased operating margins due to increased pricing pressure or other factors; our failure to perform our services or operate our business in accordance with contractual requirements, government regulations and ethical considerations; the impact of underpricing our contracts, overrunning our cost estimates or failing to receive approval for or experiencing delays with documentation of change orders; the failure of third parties to provide us critical support services; our failure to increase our market share, grow our business, successfully execute our growth strategies or manage our growth effectively; the impact of a failure to retain key executives or other personnel or recruit qualified personnel; the risks associated with our information systems infrastructure, including potential cybersecurity breaches and other disruptions which could compromise patient information or our information; risks from use of machine learning and generative artificial intelligence (“AI”), including risks from insufficient human oversight of AI or lack of controls and procedures monitoring AI use; adverse results from customer or therapeutic area concentration; the risks associated with doing business internationally, including the effects of tariffs and trade wars; the risks associated with the Foreign Corrupt Practices Act and other anti-corruption laws; future net losses; the impact of changes in tax laws and regulations; our failure to attract suitable investigators and patients to our clinical trials; the liability risks associated with our research and development services, including risks of liability resulting from harm to patients; inadequate insurance coverage for our operations and indemnification obligations; fluctuations in exchange rates; general economic conditions, including inflation, in the markets in which we and our customers operate, including financial market conditions; the impact of unfavorable economic conditions, including conditions caused by the uncertain international economic environment and current and future international conflicts; the impact of a natural disaster or other catastrophic event; negative outsourcing trends in the biopharmaceutical industry and a reduction in aggregate expenditures and research and development budgets; our inability to compete effectively with other CROs; the impact of healthcare reform; the impact of consolidation in the biopharmaceutical industry; our failure to comply with federal, state and foreign healthcare laws; the effect of current and proposed laws and regulations regarding the protection of personal data; our potential involvement in costly intellectual property lawsuits; actions by regulatory authorities or customers to limit the scope of indications related to or withdraw an approved drug, biologic or medical device from the market; and the impact of industry-wide reputational harm to CROs. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

These and other factors discussed under the caption “Risk Factors” in Item 1A, Part I of our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. If known or unknown risks or uncertainties materialize or if underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events, developments or circumstances cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures

Certain financial measures presented in this press release, such as EBITDA and EBITDA margin, are not recognized under generally accepted accounting principles in the United States of America, or U.S. GAAP. Management uses EBITDA and EBITDA margin or comparable metrics as a measurement used in evaluating our operating performance on a consistent basis, as a consideration to assess incentive compensation for our employees, for planning purposes, including the preparation of our internal annual operating budget, and to evaluate the performance and effectiveness of our operational strategies.

EBITDA and EBITDA margin have important limitations as analytical tools and you should not consider them in isolation, or as a substitute for, analysis of our results as reported under U.S. GAAP. See the condensed consolidated financial statements included elsewhere in this release for our U.S. GAAP results. Additionally, for reconciliations of EBITDA and EBITDA margin to our closest reported U.S. GAAP measures, refer to the appendix of this press release.

We believe that EBITDA and EBITDA margin are useful to provide additional information to investors about certain material non-cash and non-recurring items. While we believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors, because not all companies use identical calculations, this presentation of EBITDA and EBITDA margin may not be comparable to other similarly titled measures of other companies and should not be considered as an alternative to performance measures derived in accordance with U.S. GAAP. EBITDA is calculated as net income attributable to Medpace Holdings, Inc. before income tax expense, interest income, net, depreciation and amortization. EBITDA margin is calculated by dividing EBITDA by Revenue, net for each period. Our presentation of EBITDA and EBITDA margin should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

| |

| MEDPACE HOLDINGS, INC. AND SUBSIDIARIES |

| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) |

| | | | |

| (Amounts in thousands, except per share amounts) | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Revenue, net | $ | 716,000 | | $ | 659,903 | | | $ | 2,129,935 | | $ | 1,821,784 | |

| Operating expenses: | | | | | | | |

| Direct service costs, excluding depreciation and amortization | | 204,851 | | | 186,335 | | | | 605,680 | | | 549,977 | |

| Reimbursed out-of-pocket expenses | | 287,264 | | | 276,629 | | | | 902,407 | | | 716,505 | |

| Total direct costs | | 492,115 | | | 462,964 | | | | 1,508,087 | | | 1,266,482 | |

| Selling, general and administrative | | 51,765 | | | 48,082 | | | | 147,785 | | | 152,643 | |

| Depreciation | | 6,425 | | | 6,813 | | | | 19,731 | | | 20,284 | |

| Amortization | | 155 | | | 236 | | | | 465 | | | 709 | |

| Total operating expenses | | 550,460 | | | 518,095 | | | | 1,676,068 | | | 1,440,118 | |

| Income from operations | | 165,540 | | | 141,808 | | | | 453,867 | | | 381,666 | |

| Other income, net: | | | | | | | |

| Miscellaneous income (expense), net | | 17 | | | (489 | ) | | | 841 | | | (5,180 | ) |

| Interest income, net | | 5,349 | | | 1,517 | | | | 15,452 | | | 9,058 | |

| Total other income, net | | 5,366 | | | 1,028 | | | | 16,293 | | | 3,878 | |

| Income before income taxes | | 170,906 | | | 142,836 | | | | 470,160 | | | 385,544 | |

| Income tax provision | | 33,446 | | | 31,701 | | | | 87,468 | | | 69,554 | |

| Net income | $ | 137,460 | | $ | 111,135 | | | $ | 382,692 | | $ | 315,990 | |

| Net income per share attributable to common shareholders: | | | | | | | |

| Basic | $ | 4.92 | | $ | 3.95 | | | $ | 13.58 | | $ | 10.88 | |

| Diluted | $ | 4.84 | | $ | 3.86 | | | $ | 13.37 | | $ | 10.64 | |

| Weighted average common shares outstanding: | | | | | | | |

| Basic | | 27,940 | | | 28,136 | | | | 28,184 | | | 29,033 | |

| Diluted | | 28,372 | | | 28,817 | | | | 28,630 | | | 29,710 | |

| | | | | | | | | | | | | | |

| |

| MEDPACE HOLDINGS, INC. AND SUBSIDIARIES |

| CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) |

| | | | |

| (Amounts in thousands, except share amounts) | | | |

| | As of |

| | September 30, 2026 | | December 31, 2025 |

| ASSETS | | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 705,315 | | | $ | 497,049 | |

| Accounts receivable and unbilled, net | | 447,642 | | | | 402,078 | |

| Prepaid expenses and other current assets | | 92,043 | | | | 90,497 | |

| Total current assets | | 1,245,000 | | | | 989,624 | |

| Property and equipment, net | | 175,004 | | | | 131,055 | |

| Operating lease right-of-use assets | | 152,549 | | | | 117,815 | |

| Goodwill | | 662,396 | | | | 662,396 | |

| Intangible assets, net | | 32,955 | | | | 33,420 | |

| Deferred income taxes | | 3,272 | | | | 19,223 | |

| Other assets | | 31,419 | | | | 21,939 | |

| Total assets | $ | 2,302,595 | | | $ | 1,975,472 | |

| LIABILITIES AND SHAREHOLDERS’ EQUITY | | | |

| Current liabilities: | | | |

| Accounts payable | $ | 43,682 | | | $ | 28,142 | |

| Accrued expenses | | 443,331 | | | | 408,382 | |

| Advanced billings | | 961,855 | | | | 854,390 | |

| Other current liabilities | | 47,229 | | | | 52,834 | |

| Total current liabilities | | 1,496,097 | | | | 1,343,748 | |

| Operating lease liabilities | | 146,041 | | | | 113,643 | |

| Deferred income tax liability | | 13,657 | | | | 1,355 | |

| Other long-term liabilities | | 61,861 | | | | 57,655 | |

| Total liabilities | | 1,717,656 | | | | 1,516,401 | |

| Commitments and contingencies | | | |

| Shareholders’ equity: | | | |

| Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | | — | | | | — | |

| Common stock - $0.01 par-value; 250,000,000 shares authorized at September 30, 2026 and December 31, 2025; 27,966,686 and 28,370,780 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | | 280 | | | | 284 | |

| Treasury stock - 69,593 and 69,623 shares at September 30, 2026 and December 31, 2025, respectively | | (12,151 | ) | | | (12,156 | ) |

| Additional paid-in capital | | 978,282 | | | | 935,830 | |

| Accumulated deficit | | (373,573 | ) | | | (459,981 | ) |

| Accumulated other comprehensive loss | | (7,899 | ) | | | (4,906 | ) |

| Total shareholders’ equity | | 584,939 | | | | 459,071 | |

| Total liabilities and shareholders’ equity | $ | 2,302,595 | | | $ | 1,975,472 | |

| | | | | | | | |

| |

| MEDPACE HOLDINGS, INC. AND SUBSIDIARIES |

| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |

| | |

| (Amounts in thousands) | Nine Months Ended September 30, |

| | 2026 | | 2025 |

| CASH FLOWS FROM OPERATING ACTIVITIES: | | | |

| Net income | $ | 382,692 | | | $ | 315,990 | |

| Adjustments to reconcile net income to net cash provided by operating activities: | | | |

| Depreciation | | 19,731 | | | | 20,284 | |

| Amortization | | 465 | | | | 709 | |

| Stock-based compensation expense | | 16,870 | | | | 29,166 | |

| Noncash lease expense | | 18,063 | | | | 17,329 | |

| Deferred income tax provision | | 28,220 | | | | 63,366 | |

| Other | | 669 | | | | (433 | ) |

| Changes in assets and liabilities: | | | |

| Accounts receivable and unbilled, net | | (45,148 | ) | | | (77,119 | ) |

| Prepaid expenses and other current assets | | (2,576 | ) | | | (15,607 | ) |

| Accounts payable | | 1,469 | | | | 1,296 | |

| Accrued expenses | | 36,101 | | | | 57,521 | |

| Advanced billings | | 107,465 | | | | 123,743 | |

| Lease liabilities | | (17,807 | ) | | | (18,131 | ) |

| Other assets and liabilities, net | | (15,818 | ) | | | 2,457 | |

| Net cash provided by operating activities | | 530,396 | | | | 520,571 | |

| CASH FLOWS FROM INVESTING ACTIVITIES: | | | |

| Property and equipment expenditures | | (50,886 | ) | | | (26,820 | ) |

| Other | | 115 | | | | 153 | |

| Net cash used in investing activities | | (50,771 | ) | | | (26,667 | ) |

| CASH FLOWS FROM FINANCING ACTIVITIES: | | | |

| Proceeds from stock option exercises | | 25,590 | | | | 34,272 | |

| Repurchases of common stock | | (294,764 | ) | | | (917,389 | ) |

| Net cash used in financing activities | | (269,174 | ) | | | (883,117 | ) |

| EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS | | (2,185 | ) | | | 5,128 | |

| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | | 208,266 | | | | (384,085 | ) |

| CASH AND CASH EQUIVALENTS — Beginning of period | | 497,049 | | | | 669,436 | |

| CASH AND CASH EQUIVALENTS — End of period | $ | 705,315 | | | $ | 285,351 | |

| | | | | | | | |

| |

| MEDPACE HOLDINGS, INC. AND SUBSIDIARIES |

| RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED) |

| | | | |

| (Amounts in thousands, except percentages) | Three Months Ended September 30, | | Nine Months Ended****September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| RECONCILIATION OF GAAP NET INCOME TO EBITDA | | | | | | | |

| Net income (GAAP) | $ | 137,460 | | | $ | 111,135 | | | $ | 382,692 | | | $ | 315,990 | |

| Interest income, net | | (5,349 | ) | | | (1,517 | ) | | | (15,452 | ) | | | (9,058 | ) |

| Income tax provision | | 33,446 | | | | 31,701 | | | | 87,468 | | | | 69,554 | |

| Depreciation | | 6,425 | | | | 6,813 | | | | 19,731 | | | | 20,284 | |

| Amortization | | 155 | | | | 236 | | | | 465 | | | | 709 | |

| EBITDA (Non-GAAP) | $ | 172,137 | | | $ | 148,368 | | | $ | 474,904 | | | $ | 397,479 | |

| Net income margin (GAAP) | | 19.2 | % | | | 16.8 | % | | | 18.0 | % | | | 17.3 | % |

| EBITDA margin (Non-GAAP) | | 24.0 | % | | | 22.5 | % | | | 22.3 | % | | | 21.8 | % |

| | | | | | | | | | | | | | | | |

| |

| FY 2026 GUIDANCE RECONCILIATION (UNAUDITED) |

| | |

| (Amounts in millions, except per share amounts) | Forecast 2026 |

| | Net Income | | Net income per diluted share |

| | Low | | High | | Low | | High |

| Net income and net income per diluted share (GAAP) | $ | 514.0 | | | $ | 524.0 | | | $ | 17.97 | | $ | 18.32 |

| Income tax provision | | 119.5 | | | | 123.5 | | | | | |

| Interest income, net | | (22.9 | ) | | | (22.9 | ) | | | | |

| Depreciation | | 26.8 | | | | 26.8 | | | | | |

| Amortization | | 0.6 | | | | 0.6 | | | | | |

| EBITDA (Non-GAAP) | $ | 638.0 | | | $ | 652.0 | | | | | |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261021758492/en/

Investor Contact: David Ruhe 283-227-6472 [email protected]

Media Contact: Michael Maley 283-227-6367 [email protected]

Source: Medpace Holdings, Inc.

September 22, 2026

PDF Version

CINCINNATI--(BUSINESS WIRE)--Sep. 22, 2026-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results.

To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,500 people across 46 countries as of June 30, 2026.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260922363996/en/

Investor Contact: David Ruhe 283-227-6472 [email protected]

Media Contact: Michael Maley 283-227-6367 [email protected]

Source: Medpace Holdings, Inc.

July 22, 2026

PDF Version 273.8 KB

  • Revenue of $707.3 million in the second quarter of 2026 increased 17.2% from revenue of $603.3 million for the comparable prior-year period, representing a backlog conversion rate of 24.1%.

  • Net new business awards were $795.7 million in the second quarter of 2026, representing an increase of 28.2% from net new business awards of $620.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.13x.

  • Second quarter of 2026 GAAP net income was $121.4 million, or $4.25 per diluted share, versus GAAP net income of $90.3 million, or $3.10 per diluted share, for the comparable prior-year period. Net income margin was 17.2% and 15.0% for the second quarter of 2026 and 2025, respectively.

  • EBITDA was $153.4 million for the second quarter of 2026, an increase of 17.6% from EBITDA of $130.5 million for the comparable prior-year period, resulting in an EBITDA margin of 21.7%.

CINCINNATI--(BUSINESS WIRE)--Jul. 22, 2026-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Results

Revenue for the three months ended June 30, 2026 increased 17.2% to $707.3 million, compared to $603.3 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2026 increased 17.2% compared to the second quarter of 2025.

Backlog as of June 30, 2026 increased 4.9% to $3,014.2 million from $2,873.6 million as of June 30, 2025. Net new business awards were $795.7 million, representing a net book-to-bill ratio of 1.13x for the second quarter of 2026, as compared to $620.5 million for the comparable prior-year period. The Company calculates the net book-to-bill ratio by dividing net new business awards by revenue.

For the second quarter of 2026, total direct costs were $505.7 million, compared to total direct costs of $423.3 million in the second quarter of 2025. Selling, general and administrative (SG&A) expenses were $48.1 million in the second quarter of 2026, compared to SG&A expenses of $46.7 million in the second quarter of 2025.

GAAP net income for the second quarter of 2026 was $121.4 million, or $4.25 per diluted share, versus GAAP net income of $90.3 million, or $3.10 per diluted share, for the second quarter of 2025. This resulted in a net income margin of 17.2% and 15.0% for the second quarter of 2026 and 2025, respectively.

EBITDA for the second quarter of 2026 increased 17.6% to $153.4 million, or 21.7% of revenue, compared to $130.5 million, or 21.6% of revenue, for the comparable prior-year period. On a constant currency basis, EBITDA for the second quarter of 2026 increased 17.8% from the second quarter of 2025.

A reconciliation of the Company’s non-GAAP financial measures, including EBITDA and EBITDA margin to the corresponding GAAP measures is provided below.

Year-to-Date 2026 Financial Results

Revenue for the six months ended June 30, 2026 was $1,413.9 million, and increased 21.7% on a reported basis and 21.4% on a constant currency basis from the comparable prior-year period. Year-to-date 2026 GAAP net income was $245.2 million, or $8.53 per diluted share, compared to $204.9 million, or $6.79 per diluted share, for the comparable prior-year period. Year-to-date 2026 EBITDA was $302.8 million, or 21.4% of revenue, and increased 21.5% on a reported basis and 23.0% on a constant currency basis from the comparable prior-year period.

Balance Sheet and Liquidity

The Company’s Cash and cash equivalents were $502.7 million at June 30, 2026, and the Company generated $162.0 million in cash flow from operating activities during the second quarter of 2026.

During the second quarter of 2026, the Company repurchased 705,616 shares for a total of $294.7 million. As of June 30, 2026, the Company had $527.0 million remaining under its authorized share repurchase program.

2026 Financial Guidance

The Company forecasts 2026 revenue in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14.0% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $494.0 million to $514.0 million. Additionally, full year 2026 EBITDA is expected in the range of $618.0 million to $642.0 million. Based on forecasted 2026 revenue of $2.805 billion to $2.885 billion and GAAP net income of $494.0 million to $514.0 million, diluted earnings per share (GAAP) is forecasted in the range of $17.25 to $17.95. This guidance assumes a full year 2026 tax rate of 19.0% to 19.5%, interest income of $21.1 million, foreign exchange rates as of June 30, 2026, and 28.6 million diluted weighted average shares outstanding. This guidance does not include the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after June 30, 2026.

Conference Call Details

Medpace will host a conference call at 9:00 a.m. ET, Thursday, July 23, 2026, to discuss its second quarter 2026 results.

To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,500 people across 46 countries as of June 30, 2026.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” “forecast,” “may,” “could,” “likely,” “anticipate,” “project,” “goal,” “objective,” “potential,” “range,” “estimate,” “preliminary,” “opportunity,” “outlook,” “trend,” “can,” “might,” “drives,” “hope,” “future,” “predict” and similar expressions, and variations or negatives of these words. However, the absence of these words does not mean that a statement is not forward-looking.

These forward-looking statements are largely based on management’s current expectations and projections about future events and financial trends that we believe may affect, among other things, our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other factors that may cause our financial condition, actual results, performance (including share price performance), or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the potential loss, delay or non-renewal of our contracts, or the non-payment by customers for services we have performed; the failure to convert backlog to revenue at our present or historical conversion rate(s); the failure to maintain or generate new business awards; fluctuation in our results between fiscal quarters and years; the risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases; decreased operating margins due to increased pricing pressure or other factors; our failure to perform our services or operate our business in accordance with contractual requirements, government regulations and ethical considerations; the impact of underpricing our contracts, overrunning our cost estimates or failing to receive approval for or experiencing delays with documentation of change orders; the failure of third parties to provide us critical support services; our failure to increase our market share, grow our business, successfully execute our growth strategies or manage our growth effectively; the impact of a failure to retain key executives or other personnel or recruit qualified personnel; the risks associated with our information systems infrastructure, including potential cybersecurity breaches and other disruptions which could compromise patient information or our information; risks from use of machine learning and generative artificial intelligence (“AI”), including risks from insufficient human oversight of AI or lack of controls and procedures monitoring AI use; adverse results from customer or therapeutic area concentration; the risks associated with doing business internationally, including the effects of tariffs and trade wars; the risks associated with the Foreign Corrupt Practices Act and other anti-corruption laws; future net losses; the impact of changes in tax laws and regulations; our failure to attract suitable investigators and patients to our clinical trials; the liability risks associated with our research and development services, including risks of liability resulting from harm to patients; inadequate insurance coverage for our operations and indemnification obligations; fluctuations in exchange rates; general economic conditions, including inflation, in the markets in which we and our customers operate, including financial market conditions; the impact of unfavorable economic conditions, including conditions caused by the uncertain international economic environment and current and future international conflicts; the impact of a natural disaster or other catastrophic event; negative outsourcing trends in the biopharmaceutical industry and a reduction in aggregate expenditures and research and development budgets; our inability to compete effectively with other CROs; the impact of healthcare reform; the impact of consolidation in the biopharmaceutical industry; our failure to comply with federal, state and foreign healthcare laws; the effect of current and proposed laws and regulations regarding the protection of personal data; our potential involvement in costly intellectual property lawsuits; actions by regulatory authorities or customers to limit the scope of indications related to or withdraw an approved drug, biologic or medical device from the market; and the impact of industry-wide reputational harm to CROs. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

These and other factors discussed under the caption “Risk Factors” in Item 1A, Part I of our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. If known or unknown risks or uncertainties materialize or if underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events, developments or circumstances cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures

Certain financial measures presented in this press release, such as EBITDA and EBITDA margin, are not recognized under generally accepted accounting principles in the United States of America, or U.S. GAAP. Management uses EBITDA and EBITDA margin or comparable metrics as a measurement used in evaluating our operating performance on a consistent basis, as a consideration to assess incentive compensation for our employees, for planning purposes, including the preparation of our internal annual operating budget, and to evaluate the performance and effectiveness of our operational strategies.

EBITDA and EBITDA margin have important limitations as analytical tools and you should not consider them in isolation, or as a substitute for, analysis of our results as reported under U.S. GAAP. See the condensed consolidated financial statements included elsewhere in this release for our U.S. GAAP results. Additionally, for reconciliations of EBITDA and EBITDA margin to our closest reported U.S. GAAP measures, refer to the appendix of this press release.

We believe that EBITDA and EBITDA margin are useful to provide additional information to investors about certain material non-cash and non-recurring items. While we believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors, because not all companies use identical calculations, this presentation of EBITDA and EBITDA margin may not be comparable to other similarly titled measures of other companies and should not be considered as an alternative to performance measures derived in accordance with U.S. GAAP. EBITDA is calculated as net income attributable to Medpace Holdings, Inc. before income tax expense, interest income, net, depreciation and amortization. EBITDA margin is calculated by dividing EBITDA by Revenue, net for each period. Our presentation of EBITDA and EBITDA margin should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

| MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) |

| (Amounts in thousands, except per share amounts) | Three Months Ended June 30, | | Six Months Ended June 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Revenue, net | $ | 707,331 | | | $ | 603,311 | | | $ | 1,413,935 | | | $ | 1,161,881 | |

| Operating expenses: | | | | | | | |

| Direct service costs, excluding depreciation and amortization | | 202,555 | | | | 185,826 | | | | 400,829 | | | | 363,642 | |

| Reimbursed out-of-pocket expenses | | 303,139 | | | | 237,472 | | | | 615,143 | | | | 439,876 | |

| Total direct costs | | 505,694 | | | | 423,298 | | | | 1,015,972 | | | | 803,518 | |

| Selling, general and administrative | | 48,103 | | | | 46,664 | | | | 96,020 | | | | 104,561 | |

| Depreciation | | 6,555 | | | | 6,777 | | | | 13,306 | | | | 13,471 | |

| Amortization | | 155 | | | | 237 | | | | 310 | | | | 473 | |

| Total operating expenses | | 560,507 | | | | 476,976 | | | | 1,125,608 | | | | 922,023 | |

| Income from operations | | 146,824 | | | | 126,335 | | | | 288,327 | | | | 239,858 | |

| Other income (expense), net: | | | | | | | |

| Miscellaneous (expense) income, net | | (147 | ) | | | (2,875 | ) | | | 824 | | | | (4,691 | ) |

| Interest income, net | | 4,986 | | | | 1,078 | | | | 10,103 | | | | 7,541 | |

| Total other income (expense), net | | 4,839 | | | | (1,797 | ) | | | 10,927 | | | | 2,850 | |

| Income before income taxes | | 151,663 | | | | 124,538 | | | | 299,254 | | | | 242,708 | |

| Income tax provision | | 30,301 | | | | 34,278 | | | | 54,022 | | | | 37,853 | |

| Net income | $ | 121,362 | | | $ | 90,260 | | | $ | 245,232 | | | $ | 204,855 | |

| Net income per share attributable to common shareholders: | | | | | | | |

| Basic | $ | 4.31 | | | $ | 3.16 | | | $ | 8.66 | | | $ | 6.95 | |

| Diluted | $ | 4.25 | | | $ | 3.10 | | | $ | 8.53 | | | $ | 6.79 | |

| Weighted average common shares outstanding: | | | | | | | |

| Basic | | 28,174 | | | | 28,601 | | | | 28,308 | | | | 29,489 | |

| Diluted | | 28,554 | | | | 29,143 | | | | 28,761 | | | | 30,165 | |

| MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | | | |

| (Amounts in thousands, except share amounts) | | | |

| | As of |

| | June 30, 2026 | | December 31, 2025 |

| ASSETS | | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 502,688 | | | $ | 497,049 | |

| Accounts receivable and unbilled, net | | 441,797 | | | | 402,078 | |

| Prepaid expenses and other current assets | | 105,800 | | | | 90,497 | |

| Total current assets | | 1,050,285 | | | | 989,624 | |

| Property and equipment, net | | 157,114 | | | | 131,055 | |

| Operating lease right-of-use assets | | 125,849 | | | | 117,815 | |

| Goodwill | | 662,396 | | | | 662,396 | |

| Intangible assets, net | | 33,110 | | | | 33,420 | |

| Deferred income taxes | | 3,231 | | | | 19,223 | |

| Other assets | | 25,196 | | | | 21,939 | |

| Total assets | $ | 2,057,181 | | | $ | 1,975,472 | |

| LIABILITIES AND SHAREHOLDERS’ EQUITY | | | |

| Current liabilities: | | | |

| Accounts payable | $ | 37,527 | | | $ | 28,142 | |

| Accrued expenses | | 451,076 | | | | 408,382 | |

| Advanced billings | | 904,722 | | | | 854,390 | |

| Other current liabilities | | 42,104 | | | | 52,834 | |

| Total current liabilities | | 1,435,429 | | | | 1,343,748 | |

| Operating lease liabilities | | 120,100 | | | | 113,643 | |

| Deferred income tax liability | | 8,207 | | | | 1,355 | |

| Other long-term liabilities | | 59,584 | | | | 57,655 | |

| Total liabilities | | 1,623,320 | | | | 1,516,401 | |

| Commitments and contingencies | | | |

| Shareholders’ equity: | | | |

| Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | | — | | | | — | |

| Common stock - $0.01 par-value; 250,000,000 shares authorized at June 30, 2026 and December 31, 2025; 27,910,605 and 28,370,780 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | | 279 | | | | 284 | |

| Treasury stock - 69,593 and 69,623 shares at June 30, 2026 and December 31, 2025, respectively | | (12,151 | ) | | | (12,156 | ) |

| Additional paid-in capital | | 964,183 | | | | 935,830 | |

| Accumulated deficit | | (511,368 | ) | | | (459,981 | ) |

| Accumulated other comprehensive loss | | (7,082 | ) | | | (4,906 | ) |

| Total shareholders’ equity | | 433,861 | | | | 459,071 | |

| Total liabilities and shareholders’ equity | $ | 2,057,181 | | | $ | 1,975,472 | |

| MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |

| (Amounts in thousands) | Six Months Ended June 30, |

| | 2026 | | 2025 |

| CASH FLOWS FROM OPERATING ACTIVITIES: | | | |

| Net income | $ | 245,232 | | | $ | 204,855 | |

| Adjustments to reconcile net income to net cash provided by operating activities: | | | |

| Depreciation | | 13,306 | | | | 13,471 | |

| Amortization | | 310 | | | | 473 | |

| Stock-based compensation expense | | 9,266 | | | | 22,843 | |

| Noncash lease expense | | 11,902 | | | | 11,687 | |

| Deferred income tax provision | | 22,824 | | | | 34,856 | |

| Other | | 255 | | | | (520 | ) |

| Changes in assets and liabilities: | | | |

| Accounts receivable and unbilled, net | | (39,361 | ) | | | (81,980 | ) |

| Prepaid expenses and other current assets | | (15,949 | ) | | | (33,130 | ) |

| Accounts payable | | (45 | ) | | | 12,021 | |

| Accrued expenses | | 43,717 | | | | 12,249 | |

| Advanced billings | | 50,332 | | | | 98,198 | |

| Lease liabilities | | (12,357 | ) | | | (12,615 | ) |

| Other assets and liabilities, net | | (15,633 | ) | | | (8,046 | ) |

| Net cash provided by operating activities | | 313,799 | | | | 274,362 | |

| CASH FLOWS FROM INVESTING ACTIVITIES: | | | |

| Property and equipment expenditures | | (30,725 | ) | | | (16,107 | ) |

| Other | | 92 | | | | 100 | |

| Net cash used in investing activities | | (30,633 | ) | | | (16,007 | ) |

| CASH FLOWS FROM FINANCING ACTIVITIES: | | | |

| Proceeds from stock option exercises | | 19,094 | | | | 26,285 | |

| Repurchases of common stock | | (294,764 | ) | | | (912,815 | ) |

| Net cash used in financing activities | | (275,670 | ) | | | (886,530 | ) |

| EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | | (1,857 | ) | | | 5,069 | |

| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | | 5,639 | | | | (623,106 | ) |

| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period | | 497,049 | | | | 669,436 | |

| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period | $ | 502,688 | | | $ | 46,330 | |

| MEDPACE HOLDINGS, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED) |

| (Amounts in thousands, except percentages) | Three Months Ended June 30, | | Six Months Ended June 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| RECONCILIATION OF GAAP NET INCOME TO EBITDA | | | | | | | |

| Net income (GAAP) | $ | 121,362 | | | $ | 90,260 | | | $ | 245,232 | | | $ | 204,855 | |

| Interest income, net | | (4,986 | ) | | | (1,078 | ) | | | (10,103 | ) | | | (7,541 | ) |

| Income tax provision | | 30,301 | | | | 34,278 | | | | 54,022 | | | | 37,853 | |

| Depreciation | | 6,555 | | | | 6,777 | | | | 13,306 | | | | 13,471 | |

| Amortization | | 155 | | | | 237 | | | | 310 | | | | 473 | |

| EBITDA (Non-GAAP) | $ | 153,387 | | | $ | 130,474 | | | $ | 302,767 | | | $ | 249,111 | |

| Net income margin (GAAP) | | 17.2 | % | | | 15.0 | % | | | 17.3 | % | | | 17.6 | % |

| EBITDA margin (Non-GAAP) | | 21.7 | % | | | 21.6 | % | | | 21.4 | % | | | 21.4 | % |

| FY 2026 GUIDANCE RECONCILIATION (UNAUDITED) |

| (Amounts in millions, except per share amounts) | Forecast 2026 |

| | Net Income | | Net income per diluted share |

| | Low | | High | | Low | | High |

| Net income and net income per diluted share (GAAP) | $ | 494.0 | | | $ | 514.0 | | | $ | 17.25 | | | $ | 17.95 | |

| Income tax provision | | 117.4 | | | | 121.4 | | | | | | | | | |

| Interest income, net | | (21.1 | ) | | | (21.1 | ) | | | | |

| Depreciation | | 27.1 | | | | 27.1 | | | | | |

| Amortization | | 0.6 | | | | 0.6 | | | | | |

| EBITDA (Non-GAAP) | $ | 618.0 | | | $ | 642.0 | | | | | |

View source version on businesswire.com: https://www.businesswire.com/news/home/20260722908890/en/

Investor Contact: David Ruhe 283-227-6472 [email protected]

Media Contact: Michael Maley 283-227-6367 [email protected]

Source: Medpace Holdings, Inc.

Prompts

Medpace Holdings, Inc. (ticker MEDP), listed in United States.

ETFs Holding Medpace Holdings, Inc.

ETF Weight in ETF Shares Market value As of
AMID 3.92% 6,968 $ 4.55M Nov 18, 2026
NEWZ 3.09% 985 $ 640K Nov 18, 2026
RISN 2.86% 3,458 $ 2.054M Aug 31, 2026
CSMD 2.78% 21,874 $ 12.624M Jul 31, 2026
ALIL 2.22% 701 $ 460K Nov 18, 2026
HELX 2.15% 1,133 $ 600.025K Jun 30, 2026
ABIG 1.77% 1,612 $ 1.05M Nov 18, 2026
XOVR 1.67% 68,830 $ 36.452M Jun 30, 2026
JSMD 1.63% 29,679 $ 17.128M Jul 31, 2026
ABFL 1.40% 12,774 $ 7.372M Jul 31, 2026
ORR 1.10% 6,171 $ 4.03M Nov 18, 2026
TAX 0.94% 404 $ 239.972K Aug 31, 2026
DSTL 0.89% 35,583 $ 18.844M Jun 30, 2026
FTQI 0.86% 12,769 $ 8.277M Nov 16, 2026
SMDX 0.80% 1,560 $ 1.011M Nov 17, 2026
LSEQ 0.70% 179 $ 117.055K Nov 13, 2026
MMSC 0.59% 457 $ 296.227K Nov 16, 2026
GQI 0.55% 2,696 $ 1.428M Jun 30, 2026
BTAL short -0.47% -2,530 $ -1.34M Jun 30, 2026
OASC 0.43% 681 $ 404.507K Aug 31, 2026
TGRT 0.43% 10,659 $ 6.909M Nov 17, 2026
VFQY 0.43% 3,697 $ 2.196M Aug 31, 2026
JMEE 0.40% 17,336 $ 11.322M Nov 17, 2026
TMSL 0.38% 19,524 $ 10.34M Jun 30, 2026
SYZ 0.33% 428 $ 226.665K Jun 30, 2026
JSTC 0.30% 1,375 $ 891.275K Nov 17, 2026
FMDE 0.29% 40,503 $ 21.45M Jun 30, 2026
REMC 0.28% 18 $ 9,532.62 Jun 30, 2026
SXQG 0.24% 217 $ 142.534K Nov 12, 2026
AVMC 0.18% 1,531 $ 992.394K Nov 16, 2026
SFGV 0.16% 2,793 $ 1.82M Nov 18, 2026
DFAS 0.14% 71,393 $ 46.894M Nov 12, 2026
RILA 0.12% 88 $ 50.786K Jul 31, 2026
INFO 0.10% 1,371 $ 896.552K Nov 13, 2026
AFLG 0.10% 1,384 $ 897.109K Nov 16, 2026
TACU 0.10% 28 $ 18.15K Nov 17, 2026
AVUQ 0.09% 588 $ 381.142K Nov 16, 2026
MSSM 0.08% 995 $ 591.02K Aug 31, 2026
FYEE 0.08% 310 $ 178.904K Jul 31, 2026
DXUV 0.07% 6,366 $ 4.181M Nov 12, 2026
DFSU 0.06% 2,338 $ 1.536M Nov 12, 2026
DFAC 0.06% 78,446 $ 51.526M Nov 12, 2026
AVSU 0.05% 358 $ 232.056K Nov 16, 2026
FHEQ 0.04% 695 $ 401.091K Jul 31, 2026
AFSM 0.04% 88 $ 57.042K Nov 16, 2026
AVLC 0.04% 1,001 $ 648.848K Nov 16, 2026
DCOR 0.04% 24,753 $ 16.259M Nov 12, 2026
AVUS 0.03% 6,697 $ 4.341M Nov 16, 2026
IALT 0.03% 3,692 $ 2.393M Nov 16, 2026
DFAU 0.03% 5,809 $ 3.816M Nov 12, 2026
DUHP 0.03% 8,546 $ 5.613M Nov 12, 2026
VSLU 0.03% 270 $ 142.989K Jun 30, 2026
DFUS 0.02% 7,541 $ 4.953M Nov 12, 2026
NTSD 0.02% 12 $ 6,355.08 Jun 30, 2026
NTSX 0.02% 417 $ 220.839K Jun 30, 2026
GDE 0.02% 129 $ 76.625K Aug 31, 2026
EBI 0.01% 158 $ 93.85K Aug 31, 2026
MSLC 0.01% 914 $ 542.907K Aug 31, 2026
GVLU 0.00% 13 $ 8,426.60 Nov 17, 2026